PHARMACEUTICAL CARE FOR PATIENTS WITH CORONARY HEART DISEASE: CURRENT STATUS, CHALLENGES AND PROSPECTS
DOI:
https://doi.org/10.11603/2312-0967.2024.4.14991Keywords:
pharmaceutical care, pharmaceutical services, Coronary Heart Disease, Arterial Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Continuous Professional Development, Good Pharmacy Practice, interprofessional interaction, multidisciplinary teamsAbstract
The aim of this work is to analyze the current state of pharmaceutical care for patients with CHD and comorbid conditions, considering interprofessional approaches to develop a strategy for implementing multidisciplinary teamwork among doctors, pharmacists, and patients.
Materials and Methods. The study presents the results of an anonymous online survey of pharmacists working in pharmacies (n = 110) to assess compliance with pharmacist protocols, the current state of pharmaceutical care, and involvement in interprofessional interaction within the treatment process. Data were expanded by ESC/AHA clinical recommendations, scientific databases (Scopus, Web of Science, Cochrane Library, PubMed), and international and domestic regulatory documents. Methods applied include comparative analysis, generalization, deduction, induction, systematization, and forecasting.
Results and Discussion. The study documents individualized approaches to providing pharmaceutical care for patients with CHD, emphasizing the importance of active dialogue. It highlights the need for additional regulatory measures to enhance patient-centered team approaches and to improve pharmacists' competencies through continuous professional development (CPD).
Conclusions. Interprofessional collaboration between doctors and pharmacists is primarily observed between pharmacists in municipally owned pharmacies and healthcare institutions. Pharmacists in chain pharmacies are less frequently involved in providing pharmaceutical care. Future research should focus on integrating the entire treatment process for patients with CHD and comorbid conditions within the triad of “doctor–patient–pharmacist.”
References
World Health Organization (WHO). Non communicable diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
Institute for Health Metrics and Evaluation. GBD Results. Available from: https://vizhub.healthdata.org/gbd-results/.
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. DOI: 10.1093/eurheartj/ehad192. DOI: https://doi.org/10.1093/eurheartj/ehad192
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL. et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. DOI: 10.1161/CIR.0000000000001168. DOI: https://doi.org/10.1161/CIR.0000000000001183
Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy «Stabilna ishemichna khvoroba sertsia», Unifikovanyi klinichnyi protoko № 265 [Internet], 16 liut. 2021 (Ukraina). Available from: https://www.dec.gov.ua/wp-content/uploads/2021/12/2021_2857_ykpmd_stabihs.pdf
Bilousova NA. Pervynna profilaktyka ishemichnoi khvoroby sertsia v strukturi nadannia farmatsevtychnoi dopomohy: funktsionalne napovnennia ROLEI farmatsevta. Farmatsevt. chasopys. 2024;(3):42-52. DOI: 10.11603/2312-0967.2024.3.14862 DOI: https://doi.org/10.11603/2312-0967.2024.3.14862
International Pharmaceutical Federation (FIP). Cardiovascular diseases: A handbook for pharmacists. The Hague: International Pharmaceutical Federation; 2022. P. 108. Available from: https://www.fip.org/file/5251.
Omboni S, Caserini M. Effectiveness of pharmacists intervention in the management of cardiovascular diseases. Open Heart. Sich. 2018;5(1):e000687. DOI: 10.1136/openhrt-2017-000687 DOI: https://doi.org/10.1136/openhrt-2017-000687
Brown TJ, Todd A, OMalley C, Moore HJ, Husband AK, Bambra C, Kasim A. et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. BMJ Open. Liut. 2016;6(2):e009828. DOI: 10.1136/bmjopen-2015-009828 DOI: https://doi.org/10.1136/bmjopen-2015-009828
Mc Namara KP, Peterson GM, Hughes J, Krass I, Versace V, Clark RA, Dunbar J. Cardiovascular Disease Risk Assessment in Australian Community Pharmacy. Heart Lung Circ. Lyp. 2017;26(7):667-76. DOI: 10.1016/j.hlc.2016.10.016 DOI: https://doi.org/10.1016/j.hlc.2016.10.016
Puspitasari HP, Costa DS, Aslani P, Krass I. An explanatory model of community pharmacists support in the secondary prevention of cardiovascular disease. Res Soc Adm Pharm Sich. 2016;12(1):104-18. DOI: 10.1016/j.sapharm.2015.04.008 DOI: https://doi.org/10.1016/j.sapharm.2015.04.008
International Pharmaceutical Federation (FIP). Beating non-communicable diseases in the community – The contribution on pharmacists. The Hague: International Pharmaceutical Federation; 2019. P. 127. Available from: https://www.fip.org/files/content/publications/2019/beating-ncds-in-the-community-the-contribution-of-pharmacists.pdf.
Pro likarski zasoby, Zakon Ukrainy № 2469-IX, 28 lyp. 2022 (Ukraina). Available from: https://zakon.rada.gov.ua/laws/show/2469-20#Text
Nalezhna aptechna praktyka: Standarty yakosti aptechnykh posluh (Spilna nastanova MFF/VOOZ z NAP), Standart Vsesvitnoi orhanizatsii okhorony zdorovia [Internet], 1 sich. 2011. Available from: https://zakon.rada.gov.ua/laws/show/897_009#Text
International Pharmaceutical Federation (FIP). Economic sustainability and pharmacy: A commentary article. The Hague: International Pharmaceutical Federation; 2023. P. 21. Available from: https://www.fip.org/file/5870
Pro zatverdzhennia protokoliv farmatsevta, Nakaz MOZ Ukrainy vid 05.01.2022 r. № 7 № 7 [Internet], 5 sich. 2022 (Ukraina). Available from: https://zakon.rada.gov.ua/rada/show/v0007282-22#Text
Pro vnesennia zmin do Litsenziinykh umov provadzhennia hospodarskoi diialnosti z vyrobnytstva likarskykh zasobiv, optovoi ta rozdribnoi torhivli likarskymy zasobamy, importu likarskykh zasobiv (krim aktyvnykh farmatsevtychnykh inhrediientiv), Postanova Kabinetu Ministriv Ukrainy № 809 [Internet], 4 serp. 2023 (Ukraina). Available from: https://zakon.rada.gov.ua/laws/show/809-2023-p#Text
Mc Namara K, Alzubaidi H, Jackson JK. Cardiovascular disease as a leading cause of death: how are pharmacists getting involved? Integr Pharm Res Pract [Internet]. Liut. 2019;8:1-11. DOI: 10.2147/iprp.s133088 DOI: https://doi.org/10.2147/IPRP.S133088
Aizpurua-Arruti X, Benrimoj SC, Goyenechea E, Isla A, Oñatibia-Astibia A, Malet-Larrea A, Gastelurrutia MÁ. et al. Outcomes of Community Pharmacy Interventions on Patients with Medicines Under Additional Monitoring. Integr Pharm Res Pract. Lyp. 2024;13:115-25. DOI: 10.2147/iprp.s466129 DOI: https://doi.org/10.2147/IPRP.S466129
Liu Y, Farris KB, Nayakankuppam D, Sorofman BA, Urmie JM, Doucette WR. The approach of Norm Balance in predicting pharmacists’ intention to collaborate with physicians to improve medication therapy. Front. Pharmacol. 2024;15:1375529. DOI: 10.3389/fphar.2024.1375529 DOI: https://doi.org/10.3389/fphar.2024.1375529
Community pharmacy regulatory and practice models in eastern Europe and central Asia. Copenhagen: WHO Regional Office for Europe. [Internet] 2024. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://iris.who.int/bitstream/handle/10665/376552/9789289060776-eng.pdf?sequence=1&isAllowed=y
Committee of Ministers. Council of Europe [Internet]. Resolution CM/Res (2020)3 on the implementation of pharmaceutical care for the benefit of patients and Health services; 11 berez. 2020. Available from: https://rm.coe.int/09000016809cdf26
Henman MC, Ravera S, Lery FX. Council of Europe Resolution on the Implementation of Pharmaceutical Care—A Step Forward in Enhancing the Appropriate Use of Medicines and Patient-Centred Care. Healthcare [Internet]. 2024;12(2):232. DOI: 10.3390/healthcare12020232 DOI: https://doi.org/10.3390/healthcare12020232
Fujita K, Halvorsen KH, Sato N, Jazbar J, Modamio P, Waltering I, De Wulf I, Westerlund T, Chen TF, Teichert M. Pharmaceutical Care Network Europe definition of quality indicators for pharmaceutical care: a systematic literature review and international consensus development. Int J Clin Pharm. 2024;46(1):70-9. DOI: 10.1007/s11096-023-01631-8 DOI: https://doi.org/10.1007/s11096-023-01631-8
Hindi AM, Campbell SM, Jacobs S, Schafheutle EI. Developing a quality framework for community pharmacy: a systematic review of international literature. BMJ Open. Liut. 2024;14(2):e079820. DOI: 10.1136/bmjopen-2023-079820 DOI: https://doi.org/10.1136/bmjopen-2023-079820
Ostrowska M, Drozd M, Patryn R, Zagaja A. Prescriptions as quality indicators of pharmaceutical services in Polish community pharmacies. BMC Health Serv Res. BMC Health Serv Res. 2022;22(1):373. DOI: 10.1186/s12913-022-07772-2. DOI: https://doi.org/10.1186/s12913-022-07772-2
Shawahna R. Quality Indicators of Pharmaceutical Care for Integrative Healthcare: A Scoping Review of Indicators Developed Using the Delphi Technique. Evid Based Complement Altern Med. 2020;2020:1-20. DOI: 10.1155/2020/9131850 DOI: https://doi.org/10.1155/2020/9131850
Marques-Vidal P, Jankowski P, De Bacquer D, Kotseva K. Dietary measures among patients with coronary heart disease in Europe. ESC EORP Euroaspire V. Int J Cardiol. 2020;302:5-14. DOI: 10.1016/j.ijcard.2019.12.064 DOI: https://doi.org/10.1016/j.ijcard.2019.12.064
Ferrannini G, De Bacquer D, Vynckier P, De Backer G, Gyberg V, Kotseva K, Mellbin L. et al. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Cardiovasc Diabetol. 2021;20(1):38. DOI: 10.1186/s12933-021-01233-6 DOI: https://doi.org/10.1186/s12933-021-01233-6
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A. et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 202;28(4):370-9. DOI: 10.1177/2047487320908698. DOI: https://doi.org/10.1177/2047487320908698
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A. et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824-35. DOI: 10.1177/2047487318825350 DOI: https://doi.org/10.1177/2047487318825350
Mahanova TV, Tkachenko NO. Application trends of the systemic paradigm in pharmaceutical research. Curr Issues Pharm Med. 2023;16(1):74-82. DOI: 10.14739/2409-2932.2023.1.273576 DOI: https://doi.org/10.14739/2409-2932.2023.1.273576
Kremin Y, Lesyk L, Lesyk R, Levytska O, Hromovyk B. Detailing the Ten Main Professional Roles of a Pharmacist to Provide the Scope of Professional Functions. Sci Pharm. 2023;91(1):5. DOI: 10.3390/scipharm91010005 DOI: https://doi.org/10.3390/scipharm91010005
Budniuk O, Havrychenko D, Shcherbakov S, Olkhovska A, Mazurenko H. Optimizing Medical Goods Transportation Through Advanced Logistics Networks: A New Paradigm. Int J Relig. 2024;5(11):1262-75. DOI: 10.61707/f3n0m512 DOI: https://doi.org/10.61707/f3n0m512
Bilousova NA. Pharmaceutical care for patients with coronary heart disease: transformation of pharmaceutical practice. Curr Issues Pharm Med. 2024;17(3):282-90. DOI: 10.14739/2409-2932.2024.3.306171 DOI: https://doi.org/10.14739/2409-2932.2024.3.306171
Tkachenko N, Pankevych O, Mahanova T, Hromovyk B, Lesyk R, Lesyk L. Human Healthcare and Its Pharmacy Component from a Safety Point of View. Pharmacy. 2024;12(2):64. DOI: 10.3390/pharmacy12020064 DOI: https://doi.org/10.3390/pharmacy12020064
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
